Omni Partners Llp Has Lifted Time Warner (TWX) Stake By $53.97 Million; Aeglea Biotherapeutics (AGLE) Sellers Increased By 15.62% Their Shorts

March 23, 2018 - By Maria Brooks

Omni Partners Llp increased Time Warner Inc (TWX) stake by 141.34% reported in 2017Q3 SEC filing. Omni Partners Llp acquired 529,111 shares as Time Warner Inc (TWX)’s stock rose 1.19%. The Omni Partners Llp holds 903,465 shares with $92.56 million value, up from 374,354 last quarter. Time Warner Inc now has $72.86B valuation. The stock decreased 0.88% or $0.83 during the last trading session, reaching $93.43. About 2.90 million shares traded. Time Warner Inc. (NYSE:TWX) has risen 36.37% since March 23, 2017 and is uptrending. It has outperformed by 19.67% the S&P500.

Aeglea Biotherapeutics Inc (NASDAQ:AGLE) had an increase of 15.62% in short interest. AGLE’s SI was 44,400 shares in March as released by FINRA. Its up 15.62% from 38,400 shares previously. With 77,600 avg volume, 1 days are for Aeglea Biotherapeutics Inc (NASDAQ:AGLE)’s short sellers to cover AGLE’s short positions. The SI to Aeglea Biotherapeutics Inc’s float is 0.67%. The stock decreased 1.33% or $0.14 during the last trading session, reaching $10.36. About 44,269 shares traded. Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE) has declined 11.96% since March 23, 2017 and is downtrending. It has underperformed by 28.66% the S&P500.

Among 4 analysts covering Aeglea BioTherapeutics (NASDAQ:AGLE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeglea BioTherapeutics had 4 analyst reports since May 2, 2016 according to SRatingsIntel. The rating was initiated by Needham on Monday, May 9 with “Buy”. The firm earned “Outperform” rating on Monday, May 2 by Wells Fargo. The rating was initiated by UBS on Monday, May 2 with “Buy”. The stock has “Outperform” rating by BMO Capital Markets on Monday, May 2.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company has market cap of $173.18 million. The Company’s human enzymes are designed to degrade specific amino acids in the blood. It currently has negative earnings. The companyÂ’s lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies.

Since December 14, 2017, it had 0 buys, and 3 sales for $2.88 million activity. $376,219 worth of Time Warner Inc. (NYSE:TWX) was sold by WRIGHT DEBORAH C on Monday, February 12. 23,450 shares were sold by OLAFSSON OLAF, worth $2.11M on Thursday, December 14. 4,019 shares were sold by BARR WILLIAM P, worth $390,647.

Investors sentiment increased to 0.91 in 2017 Q3. Its up 0.15, from 0.76 in 2017Q2. It improved, as 66 investors sold TWX shares while 374 reduced holdings. 69 funds opened positions while 264 raised stakes. 586.69 million shares or 2.23% less from 600.08 million shares in 2017Q2 were reported. Ionic Ltd has 0.4% invested in Time Warner Inc. (NYSE:TWX) for 96,907 shares. Cypress Grp Incorporated holds 0.14% or 6,595 shares in its portfolio. Principal Finance Gp has 1.89 million shares. Laurion Cap Lp holds 0.14% or 309,694 shares. Norinchukin Savings Bank The reported 97,373 shares stake. Stevens First Principles Investment Advsr owns 93 shares. Point72 Asset Mgmt LP accumulated 4.48M shares. Waldron LP owns 2,247 shares or 0.06% of their US portfolio. Vertex One Asset Mngmt Incorporated stated it has 242,060 shares or 4.04% of all its holdings. Axa has 181,882 shares. Crestpoint Cap Management Ltd Llc has invested 0.69% in Time Warner Inc. (NYSE:TWX). Citadel Advsr Limited Liability accumulated 3.02 million shares. Interocean Ltd Llc has invested 0.29% in Time Warner Inc. (NYSE:TWX). Tig Advsrs Lc reported 2.62M shares. Bahl And Gaynor Inc accumulated 0.03% or 26,069 shares.

Among 40 analysts covering Time Warner Inc. (NYSE:TWX), 18 have Buy rating, 0 Sell and 22 Hold. Therefore 45% are positive. Time Warner Inc. had 123 analyst reports since August 6, 2015 according to SRatingsIntel. On Thursday, February 1 the stock rating was maintained by Guggenheim with “Buy”. Pivotal Research upgraded Time Warner Inc. (NYSE:TWX) on Tuesday, November 14 to “Buy” rating. The stock has “Buy” rating by M Partners on Monday, August 3. The stock has “Hold” rating by RBC Capital Markets on Thursday, February 1. The stock of Time Warner Inc. (NYSE:TWX) has “Hold” rating given on Monday, November 20 by KeyBanc Capital Markets. As per Thursday, August 3, the company rating was downgraded by Jefferies. On Tuesday, July 26 the stock rating was downgraded by FBR Capital to “Market Perform”. The stock of Time Warner Inc. (NYSE:TWX) has “Hold” rating given on Friday, October 27 by Cowen & Co. The rating was maintained by Jefferies on Tuesday, May 23 with “Buy”. Goldman Sachs downgraded the stock to “Neutral” rating in Monday, October 24 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts